Stockscreener 앱 받기
10.92
4.35%
-0.4895
전일 마감가:
$11.41
열려 있는:
$11.2
하루 거래량:
2.27M
Relative Volume:
0.85
시가총액:
$1.90B
수익:
$61.10M
순이익/손실:
$-138.36M
주가수익비율:
-8.0893
EPS:
-1.35
순현금흐름:
$-90.59M
1주 성능:
-5.35%
1개월 성능:
-4.35%
6개월 성능:
+24.01%
1년 성능:
+6.26%
1일 변동 폭
$10.40
$11.36
1주일 범위
$10.40
$12.10
52주 변동 폭
$5.80
$13.85
Ocular Therapeutix Inc Stock (OCUL) Company Profile
명칭
Ocular Therapeutix Inc
전화
781-357-4000
주소
15 CROSBY DRIVE, BEDFORD, MA
OCUL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
10.92 | 2.42B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.19 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.41 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
424.76 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
836.58 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.94 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-15 | 개시 | Chardan Capital Markets | Buy |
| 2025-04-08 | 개시 | William Blair | Outperform |
| 2025-03-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-03-11 | 개시 | Needham | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-20 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-05-31 | 재개 | Piper Sandler | Overweight |
| 2024-02-09 | 개시 | BofA Securities | Buy |
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-08-10 | 재개 | Berenberg | Buy |
| 2021-08-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-11-13 | 재확인 | Raymond James | Strong Buy |
| 2020-08-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-03 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2019-05-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-21 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-11-15 | 개시 | Raymond James | Strong Buy |
| 2018-09-07 | 개시 | Piper Jaffray | Overweight |
| 2017-10-24 | 개시 | Guggenheim | Buy |
| 2017-07-26 | 개시 | H.C. Wainwright | Buy |
| 2017-07-12 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-06-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-08-11 | 개시 | JMP Securities | Mkt Outperform |
| 2016-02-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | 개시 | Morgan Stanley | Overweight |
모두보기
Ocular Therapeutix Inc 주식(OCUL)의 최신 뉴스
Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates - sharewise.com
Earnings call transcript: Ocular Therapeutix Q3 2025 sees mixed results, stock dips - Investing.com
Ocular Therapeutix: Q3 Earnings Snapshot - KVUE
Ocular Therapeutix Inc. Q3 Loss Increases, Misses Estimates - Nasdaq
Ocular Therapeutix completes randomization target for wet AMD drug trial - Investing.com
Earnings Flash (OCUL) Ocular Therapeutix, Inc. Reports Q3 Revenue $14.5M, vs. FactSet Est of $14.6M - MarketScreener
OCULAR THERAPEUTIX, INC SEC 10-Q Report - TradingView
Ocular Therapeutix Reports Third Quarter 2025 Financial Results and Business Highlights - TradingView
Ocular TherapeutixSOL-R Trial On Track For Topline Data In 1H 2027 - TradingView
Multi asset correlation models including Ocular Therapeutix Inc.July 2025 Selloffs & Risk Controlled Daily Plans - newser.com
Ocular Therapeutix Advances AXPAXLI™ Development in Wet AMD with SOL-R Trial Milestone and Upcoming Data in 2027 - Quiver Quantitative
Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights - GlobeNewswire
Ocular Therapeutix (NASDAQ: OCUL) hits 555 SOL-R randomizations; topline data planned 1H 2027 - Stock Titan
Will Ocular Therapeutix Inc. stock see insider buyingJuly 2025 News Drivers & Safe Entry Trade Signal Reports - newser.com
Short interest data insights for Ocular Therapeutix Inc.Trade Exit Report & Safe Entry Zone Identification - newser.com
Can Ocular Therapeutix Inc. (0OT) stock beat analyst consensusCEO Change & Safe Capital Preservation Plans - newser.com
Why analysts upgrade Ocular Therapeutix Inc. stockQuarterly Portfolio Review & Fast Gain Stock Tips - newser.com
What institutional flow reveals about Ocular Therapeutix Inc.July 2025 Snapshot & Daily Risk Controlled Trade Plans - newser.com
What RSI levels show for Ocular Therapeutix Inc. (0OT) stockWeekly Trade Summary & Accurate Entry and Exit Point Alerts - newser.com
Is this a good reentry point in Ocular Therapeutix Inc.Quarterly Profit Report & Stepwise Entry/Exit Trade Alerts - newser.com
Is Ocular Therapeutix Inc. stock undervalued vs historical averages2025 Investor Takeaways & Growth Focused Stock Pick Reports - newser.com
Can Ocular Therapeutix Inc. hit a new high this monthJuly 2025 Institutional & Accurate Technical Buy Alerts - newser.com
Ocular Therapeutix Inc (OCUL) Q3 2025 Earnings Report Preview: What To Expect - GuruFocus
Hydrogel-Based Drug Delivery System Market Set to Witness - openPR.com
Will Ocular Therapeutix Inc. stock go up soonInflation Watch & Low Risk High Win Rate Picks - newser.com
Why Ocular Therapeutix Inc. stock appeals to analystsJuly 2025 Rallies & Long-Term Investment Growth Plans - newser.com
Detecting support and resistance levels for Ocular Therapeutix Inc.Trade Signal Summary & Entry Point Strategy Guides - newser.com
How to interpret RSI for Ocular Therapeutix Inc. stock2025 Big Picture & Safe Capital Growth Trade Ideas - newser.com
What Ocular Therapeutix (OCUL)'s SOL-1 Trial Milestone and Capital Raise Mean for Shareholders - Sahm
Is Ocular Therapeutix Inc. stock oversold or undervalued2025 Trading Volume Trends & Daily Growth Stock Tips - newser.com
Real time scanner hits for Ocular Therapeutix Inc. explainedAnalyst Upgrade & High Accuracy Swing Trade Signals - newser.com
How to recover losses in Ocular Therapeutix Inc. stockJuly 2025 Sector Moves & Community Consensus Trade Alerts - newser.com
How Ocular Therapeutix Inc. (0OT) stock responds to job market shiftsJuly 2025 PreEarnings & Stepwise Entry and Exit Trade Signals - newser.com
Is Ocular Therapeutix Inc. (0OT) stock positioned for digital growth eraWeekly Trade Recap & Daily Risk Controlled Trade Plans - newser.com
Ocular Therapeutix Inc (OCUL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.92%
0.47%
자본화:
|
볼륨(24시간):